What is the ORIGIN 3 study?

The ORIGIN 3 clinical research study is for people who have been diagnosed with IgAN and are seeking a new IgA Nephropathy medication or therapy.

The study will test a new investigational medication, atacicept, to learn if it can preserve kidney function in people with IgAN.

This is a Phase 3 study, which means there have been at least two smaller in-human trials evaluating the investigational medication for people with IgAN.

In the Phase 2b portion of the ORIGIN study evaluating atacicept in 116 people with IgAN, atacicept showed a reduction in the amount of protein in their urine, which may indicate improved kidney function. However, more clinical data is needed to validate the effect of the study medication.

Who can join the ORIGIN 3 study?

You may be able to join the study if you meet the following requirements:

18 years or older

Diagnosed with IgAN, confirmed by a kidney biopsy within the past 10 years

On a stable, prescribed regimen of an ACE inhibitor or ARB medication for blood pressure for at least 3 months

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker.

Other study requirements will apply — the study clinic will determine if you're eligible.

See if you may be eligible

What will happen during the study?

If you join the study, your participation will last about 3 and a half years total.

Study participants can expect the following:

Review & sign the Informed Consent Form

Screening (up to 1 month)
‍
Visit the study clinic and complete assessments to confirm you can enroll in the study.

Blinded dosing period (2 years)

Receive 1 weekly injection of atacicept or placebo while continuing your current standard of care therapy. You will visit the study clinic regularly for assessments to help the study team determine how your body is reacting to the study medication.

Open-label extension period (1 year)

About 2 years after your first dose of atacicept or placebo, you may be eligible to enter the open-label extension period. During this period, all participants receive atacicept. You will continue to visit the study clinic regularly for assessments.

Follow-up period (6 months)

After your last dose of atacicept, you will attend 2 follow-up visits at the study clinic. During these visits, you will complete assessments similar to others completed during the study.

If you decide to take part in the study, you will receive at no cost:

Once-weekly injections of the study medication or placebo
Regular assessments at the study clinic
Study support and monitoring by a healthcare team

You may be reimbursed for your time and travel.

Participation in a clinical study is voluntary.
You can ask any questions you have and may leave the study at any time, for any reason.

⟶ Learn more about taking part in clinical research

ORIGIN 3 Study

What is the ORIGIN 3 study?

Who can join the ORIGIN 3 study?

What will happen during the study?